Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study

医学 安慰剂 视神经脊髓炎 内科学 子群分析 危险系数 随机对照试验 随机化 人口 光谱紊乱 物理疗法 儿科 多发性硬化 精神科 置信区间 病理 替代医学 环境卫生
作者
Kazuo Fujihara,Ho Jin Kim,Takahiko Saida,Tatsuro Misu,Yoshito Nagano,Naoko Totsuka,Masato Iizuka,Shinsuke Kido,Ryuuji Terata,Kyoko Okumura,Shinya Hirota,Bruce Cree
出处
期刊:Multiple sclerosis and related disorders [Elsevier BV]
卷期号:79: 104938-104938 被引量:7
标识
DOI:10.1016/j.msard.2023.104938
摘要

BACKGROUND: Inebilizumab, an anti-CD19 B cell-depleting antibody, reduced the risk of a neuromyelitis optica spectrum disorder (NMOSD) attack, disability worsening, magnetic resonance imaging (MRI) lesion activity, and disease-related hospitalizations in participants with NMOSD in the N-MOmentum study (NCT02200770). However, the efficacy and safety outcomes of inebilizumab specific to an Asian population were not fully reported. Therefore, subgroup analyses of the N-MOmentum study were conducted post hoc to evaluate the efficacy and safety of inebilizumab in Asian participants with NMOSD. METHODS: The N-MOmentum study was a multicenter, double-blind, randomized, placebo-controlled phase 2/3 trial with an open-label extension period (OLP). In the subgroup analyses, data from Asian participants from the N-MOmentum study were compared with those of non-Asian participants. Eligible participants were randomly allocated (3:1) to receive 300 mg intravenous (IV) inebilizumab or placebo on Days 1 and 15. Participants who had an NMOSD attack or completed the randomized controlled period (RCP) could enter the OLP, where they received inebilizumab for ≥2 years. All participants who entered the OLP received inebilizumab 300 mg IV every 6 months. RESULTS: Overall, 230 participants received treatment (174 received inebilizumab and 56 received placebo), of whom 47 were Asian (39 received inebilizumab and 8 received placebo). Baseline characteristics were similar between the Asian and non-Asian subgroups, except for disease duration, annualized relapse rate prior to randomization in this study, and previous maintenance therapy. In the Asian subgroup, the risk of NMOSD attacks was reduced with inebilizumab versus placebo (hazard ratio, 0.202) and the attack-free rate at 28 weeks was 82.1% with inebilizumab versus 37.5% with placebo, in the 6-month RCP. NMOSD attack rates were comparable between the Asian and non-Asian subgroups. In the Asian subgroup, the rates of Expanded Disability Status Scale worsening from baseline, active MRI lesions, and disease-related hospitalizations tended to be lower in the inebilizumab group than in the placebo group; similar results were shown in the non-Asian subgroup. For long-term efficacy and safety (RCP and OLP), the annualized adjudicated NMOSD attack rate in Asian participants treated with inebilizumab was reduced (0.096) compared with that at baseline (1.04), with a mean follow-up period of inebilizumab treatment of 3.38 years, which was consistent with the results in the non-Asian subgroup. The risk of NMOSD attack decreased with prolonged duration of treatment in both the inebilizumab/inebilizumab and placebo/inebilizumab groups in the Asian and non-Asian subgroups. The incidence of treatment-emergent adverse events (TEAEs) was similar between the Asian and non-Asian subgroups. In the Asian and non-Asian subgroups, 15.2% and 35.2% of participants, respectively, had at least one serious TEAE and/or Grade ≥3 TEAE during long-term therapy. No deaths occurred in the Asian subgroup whereas three deaths occurred in the non-Asian subgroup. CONCLUSION: Inebilizumab reduced the risk of an NMOSD attack, progression of disability, MRI lesion activity, and disease-related hospitalizations in Asian participants with NMOSD. The efficacy of inebilizumab in reducing NMOSD attacks continued without any unexpected safety signals or concerns during long-term use in Asian participants.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
听海余温完成签到,获得积分10
刚刚
刚刚
刚刚
刚刚
Code_king发布了新的文献求助10
1秒前
Code_king发布了新的文献求助10
1秒前
Code_king发布了新的文献求助10
1秒前
1秒前
1秒前
AAA完成签到,获得积分10
1秒前
dreamvssnow发布了新的文献求助10
1秒前
1秒前
1秒前
科研通AI6.3的应助被赵一铭采纳,获得10
1秒前
2秒前
科研小白发布了新的文献求助10
2秒前
2秒前
2秒前
歪西西发布了新的文献求助10
3秒前
3秒前
Code_king发布了新的文献求助10
3秒前
4秒前
Code_king发布了新的文献求助10
4秒前
Code_king发布了新的文献求助10
4秒前
快乐海云发布了新的文献求助10
4秒前
Code_king发布了新的文献求助10
4秒前
5秒前
Code_king发布了新的文献求助10
5秒前
Code_king发布了新的文献求助10
5秒前
Code_king发布了新的文献求助10
5秒前
刘天煜发布了新的文献求助30
6秒前
Code_king发布了新的文献求助10
6秒前
爆米花的应助被dreamvssnow采纳,获得10
6秒前
Orange的应助被开开开采纳,获得10
6秒前
无极微光的应助被庆庆采纳,获得20
6秒前
Code_king发布了新的文献求助10
6秒前
粒子发布了新的文献求助10
6秒前
Code_king发布了新的文献求助10
6秒前
海绵发布了新的文献求助10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176481
求助须知:如何正确求助?哪些是违规求助? 9567855
关于积分的说明 21795109
捐赠科研通 7771163
什么是DOI,文献DOI怎么找? 3432027
关于科研通互助平台的介绍 2556365
邀请新用户注册赠送积分活动 2477695